Skip to main content
SpringerLink
Log in

Hormone Replacement Therapy and Breast and Gynecologic Cancers

  • Chapter
Women’s Health and Menopause

Part of the book series: Medical Science Symposia Series ((MSSS,volume 11))

Abstract

The most serious obstacle to the diffusion of hormone replacement therapy (HRT) in menopause is the concern that HRT, either estrogens alone or combined with progestins, may enhance morbidity and mortality due to the development of malignant neoplasia in reproductive organs, particular breast and endometrial cancer. We reviewed the literature on breast and gynecological cancer risk for HRT users, specifically addressing the issues of duration, dose, and type of hormonal compounds in influencing cancer risk.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Cline JM, Soderqwist G, von Schoultz E, et al. Effects of hormone replacement therapy on the mammary gland of surgically postmenopausal cynomolgus macaques. Am J Obstet Gynecol 1996;174:93–100.

    Article  PubMed  CAS  Google Scholar 

  2. Toniolo PG, Levitz M, Zeleniuch-Jacquotte A, et al. A prospective study of endogenous estrogens and breast cancer in postmenopausal women. J Natl Cancer Inst 1985;87:190–97.

    Article  Google Scholar 

  3. Armstrong B. Oestrogen therapy after the menopause-boon or bane? Med J Aust 1988;148:213–14.

    PubMed  CAS  Google Scholar 

  4. Dupont WD, Page DL. Menopausal estrogen replacement therapy and breast cancer. Arch Intern Med 1988;151:67–72.

    Article  Google Scholar 

  5. Steinberg KK, Thacker SB, Smith S J, et al. A meta-analysis of the effect of estrogen replacement therapy on the risk of breast cancer. JAMA 1991;265:1985–90.

    Article  PubMed  CAS  Google Scholar 

  6. Grady D, Rubin SM, Petitti DB, et al. Hormone therapy to prevent disease and prolong life in postmenopausal women. Ann Intern Med 1992; 117:1016–37.

    PubMed  CAS  Google Scholar 

  7. Sillero-Arenas M, Delgado-Rodriguez M, Rodriguez-Canteras R, Bueno-Cavanillas A, Galvez-Vergas R. Menopausal hormone replacement therapy and breast cancer: A metaanalysis. Obstet Gynecol 1992;79:286–94.

    PubMed  CAS  Google Scholar 

  8. Colditz GA, Egan KM, Stampfer MJ, et al. Hormone replacement therapy and risk of breast cancer: Results from epidemiologic studies. Am J Obstet Gynecol 1993; 168:1473–80.

    PubMed  CAS  Google Scholar 

  9. Colditz GA, Hankinson SE Hunter DJ, et al. The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. NEJM 1995;332:1589–93.

    Article  PubMed  CAS  Google Scholar 

  10. La Vecchia C, Negri E, Franceschi S, et al. Hormone replacement treatment and breast cancer risk: A cooperative Italian study. Br J Cancer 1995;72:244–48.

    Article  PubMed  Google Scholar 

  11. Stanford J, Weiss N, Voigt L, et al. Combined estrogen and progestin hormone replacement therapy in relation to risk of breast cancer in middle-aged women. JAMA 1995;274:137–42.

    Article  PubMed  CAS  Google Scholar 

  12. Newcomb PA, Longnecker MP, Storer BE, et al. Long term hormone replacement therapy and risk of breast cancer in post menopausal women. Am J Epidemiol 1995; 142:788–95.

    PubMed  CAS  Google Scholar 

  13. Schunrmans A, Van den Brandt P, Goldbohm R. Exogenous hormone use and the risk of postmenopausal breast cancer: Results from the Netherlands cohort study. Cancer Causes Contr 1995;6:416–24.

    Article  Google Scholar 

  14. Persson I, Yuen J, Bergkvist L, Schairer C. Cancer incidence and mortality in women receiving estrogen and estrogen-progestin replacement therapy — long-term follow-up of a Swedish cohort. Int J Cancer 1996;67(3):327–32.

    Article  PubMed  CAS  Google Scholar 

  15. Kennedy DL, Baum C, Forbes MB. Non-contraceptive estrogens and progestins: Use patterns overtime. Obstet Gynecol 1985;65:441.

    PubMed  CAS  Google Scholar 

  16. Weissemberger AJ, Ho KKY, Lazarus L. Contrasting effects of oral and transdermal routes of estrogen replacement therapy on 24-hour growth hormone (GH) secretion, insuline-like growth factor I, and GH binding protein in postmenopausal women. J Clin Endocrinol Metab 1991;72:374–81.

    Article  Google Scholar 

  17. Campagnoli C, Biglia N, Peris C, Sismondi P. Potential impact on breast cancer risk of circulating insulin-like growth factor I modifications induced by oral HRT in menopause. Gynecol Endocrinol 1995;9:67–74.

    Article  PubMed  CAS  Google Scholar 

  18. Campagnoli C, Biglia N, Altare F, et al. Differential effects of oral conjugated estrogens and transdermal estradiol on insulin-like growth factor I, growth hormone and sex hormone binding globulin serum levels. Gynecol Endocrinol 1993;7:251–58.

    Article  PubMed  CAS  Google Scholar 

  19. Staffa JA, Newschaffer CJ, Jones JK, Miller V. Progestins and breast cancer: An epidemiologic review. Fertil Steril 1992;57:473–91.

    PubMed  CAS  Google Scholar 

  20. Sitruk-Ware R. Estrogens, progestins and breast cancer risk in post-menopausal women: State of the ongoing controversy in 1992. Maturitas 1992;15:129–39.

    Article  PubMed  CAS  Google Scholar 

  21. Palmer JL, Rosenberg L, Clarke EA, et al. Breast cancer risk after estrogen replacement therapy: Result from the Toronto breast cancer study. Am JEpidemiol 1991;134:1386.

    CAS  Google Scholar 

  22. Natchtigall MJ, Smilen SW, Nachtigall RD, et al. Incidence of breast cancer in a 22-year study of women receiving estrogen-progestin replacement therapy. Obstet Gynecol 1992;80:827–30.

    Google Scholar 

  23. Gambrell R, Maier RC, Sanders BI, et al. Decreased incidence of breast cancer in postmenopausal estrogen-progestogen users. Obstet Gynecol 1983;62:435–43.

    PubMed  Google Scholar 

  24. Bergkvist L, Adami HO, Persson I, et al. The risk of breast cancer after estrogen and estrogen-progestin replacement. NEJM 1989;321:293–97.

    Article  PubMed  CAS  Google Scholar 

  25. Ewertz M. Influence of non-contraceptive exogenous and endogenous sex hormones on breast cancer risk in Denmark. Int J Cancer 1988;42:832–38.

    Article  PubMed  CAS  Google Scholar 

  26. Colditz GA, Stampfer MJ, Willet WC, et al. Type of postmenopausal hormone use and risk of breast cancer: 12-year follow-up from the Nurses’ Health Study. Cancer Causes Control 1992;3:433–39.

    Article  PubMed  CAS  Google Scholar 

  27. Bergkvist L, Adami HO, Person I, Bergstrom R, Krusemo UB. Prognosis after breast cancer diagnosis in women exposed to estrogen and estrogen-progestogen replacement therapy. Am JEpidemiol 1989;130:221–28.

    CAS  Google Scholar 

  28. Henderson BE, Paganini-Hill A, Ross RK. Decreased mortality in users of estrogen replacement. Arch Intern Med 1991;151:75–78.

    Article  PubMed  CAS  Google Scholar 

  29. Bonnier P, Romain S, Giacalone PL, et al. Clinical and biologic prognostic factors in breast cancer diagnosed during postmenopausal hormone replacement therapy. Obstet Gynecol 1995;85(1):11–7.

    Article  PubMed  CAS  Google Scholar 

  30. Potischman N, Hoover M, Brinton LA, et al. Case-control study of endogenous steroid hormones and endometrial cancer. JNCI 1996;88(16): 1127–35.

    Article  PubMed  CAS  Google Scholar 

  31. Grady D, Gebretsadik T, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: A meta-analysis. Obstet Gynecol 1995;85:304–13.

    Article  PubMed  CAS  Google Scholar 

  32. Hammond C, Jelovsek F, Lee K, et al. Effects of long-term estrogen replacement therapy. II Neoplasia. Am J Obstet Gynecol 1979;133:537–47.

    PubMed  CAS  Google Scholar 

  33. Nachtigall L, Nachtigall RH, Nachtigall RD, et al. Estrogen replacement therapy II: A prospective study in the relationship to carcinoma and cardiovascular and metabolic problems. Obstet Gynecol 1979;54:74–9.

    Article  PubMed  CAS  Google Scholar 

  34. Voigt L, Weiss N, Chu J, et al. Progestogen supplementation of exogenous estrogens and risk of endometrial cancer. Lancet 1991;338:274–77.

    Article  PubMed  CAS  Google Scholar 

  35. Jick S, Walker A, Jick H. Estrogens, progesterone, and endometrial cancer. Epidemiology 1993;4:20–24.

    Article  PubMed  CAS  Google Scholar 

  36. Brinton L, Hoover R. Estrogen replacement therapy and endometrial cancer risk: Unresolved issues. Obstet Gynecol 1993;81:265–71.

    PubMed  CAS  Google Scholar 

  37. Gambrell R Jr, Massey F, Castaneda T, et al. Use of the progestogen challenge test to reduce the risk of endometrial cancer. Obstet Gynecol 1980;55:732–38.

    PubMed  Google Scholar 

  38. Persson I, Adami HO, Bergkvist L, et al. Risk of endometrial cancer after treatment with oestrogehs alone or in conjunction with progestogens: Results of a prospective study. BMY 1989;298:147–51.

    Article  CAS  Google Scholar 

  39. The Writing Group for the PEPI Trial. Effects of HRT on endometrial histology in postmenopausal women. The postmenopausal estrogen/progestin interventions (PEPI) trial. JAMA 1996;275(5):370–75.

    Article  Google Scholar 

  40. Gibbons WE, Moyer DL, Lobo RA, et al. Biochemical and histology effects of sequential estrogeti/progestin therapy on the endometrium of postmenopausal women. Am J Obstet Gynecol 1986;154:456–61.

    PubMed  CAS  Google Scholar 

  41. Woordruff JD, Pickar JH. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxy-progesterone acetate or conjugated estrogens alone. Am J Obstet Gynecol. 1994;170:1213–23.

    Google Scholar 

  42. Cerin Heldas K, Moeller B. Adverse endometrial effects of long cycle estrogen and progestogen replacement therapy. New Eng J Med 1996;334:668–69.

    Article  PubMed  CAS  Google Scholar 

  43. Whittemore AS, Harris R, Intyre J. Collaborative Ovarian Cancer Group. Characteristics relating to ovarian cancer risk: Collaborative analysis of 12 US case-control studies. Am J Epidemiol 1992;136:1184–1203.

    PubMed  CAS  Google Scholar 

  44. Thomas DB. Estrogen replacement therapy and cancer: Endometrial, breast and ovarian. In: Kerenman SG, editor. Proceedings of the Symposium on The Menopause, Napa CA, March 1989, Serono Symposia 1990; 101–21.

    Google Scholar 

  45. Hildreth NG, Kelsey JL, Li Volsi VA, et al. An epidemiologic study on epithelial carcinoma of the ovary. Am J Epidemiol 1981;114:398–405.

    PubMed  CAS  Google Scholar 

  46. Wu ML, Whittemore AS, Paffenbarger RS, et al. Personal and environmental characteristics related to epithelial ovarian cancer. Am J Epidemiol 1988; 128:1216–27.

    PubMed  CAS  Google Scholar 

  47. Purdie D, Green A, Bain C, et al. Reproductive and other factors and risk of epithelial ovarian cancer: An Australian case-control study. Int J Cancer 1995;62:678–84.

    Article  PubMed  CAS  Google Scholar 

  48. Hartge P, Hoover R, McGowan L, et al. Menopause and ovarian cancer Am J Epidemiol 1988;127:990–98.

    PubMed  CAS  Google Scholar 

  49. Smith EM, Sowers MF, Burns TL. Effects of smoking on the development of female reproductive cancers. JNCI 1984;73:371–76.

    PubMed  CAS  Google Scholar 

  50. Cramer DW, Hutchinson GB, Welch WR, et al. Determinants of ovarian cancer risk. 1: Reproductive experiences and family history. JNCI 1983;71:711–16.

    PubMed  CAS  Google Scholar 

  51. Booth M, Berai V, Smith P. Risk factor for ovarian cancer: A case-control study. Br J Cancer 1989;60:592–98.

    Article  PubMed  CAS  Google Scholar 

  52. Polychronopoulou A, Tzonou A, Hsieh C, et al. Reproductive variables, tobacco, ethanol, coffee and somatometry as risk factors for ovarian cancer. Int J Cancer 1993;55:402–7.

    Article  PubMed  CAS  Google Scholar 

  53. Kaufman DW, Kelly JP, Welch WR, et al. Non-contraceptive estrogen use and epithelial ovarian cancer. Am J Epidemiol 1989;130:1142–51.

    PubMed  CAS  Google Scholar 

  54. Parazzini F, La Vecchia C, Negri E, et al. Estrogen replacement therapy and ovarian cancer. Int J Cancer 1994;57:135–36.

    Article  PubMed  CAS  Google Scholar 

  55. Rodriguez C, Calle E, Coates RJ, et al. Estrogen replacement therapy and fatal ovarian cancer. Am J Epidemiol 1995;141:823–35.

    Google Scholar 

  56. Hunt K, Vessey M, McPherson K, et al. Long-term surveillance of mortality and cancer incidence in women receiving HRT. Br J Obstet Gynecol 1987;94:620–35.

    Article  CAS  Google Scholar 

  57. Newcomb PA, Weiss NS, Daling JR. Incidence of vulvar carcinoma in relation to menstrual, reproductive and medical factors. JNCI 1984;73:391–96.

    PubMed  CAS  Google Scholar 

  58. Brinton LA, Nasca PC, Mallin K, et al. Case-control study of cancer of the vulva. Obstet Gynecol 1990;75:859–66.

    PubMed  CAS  Google Scholar 

  59. Sherman KJ, Daling JR, McKnight B, Chu J. Hormonal factors in vulvar cancer. A case-control study. J Reprod Med 1994;39:857–61.

    PubMed  CAS  Google Scholar 

  60. Weiss N, Hill D. Postmenopausal estrogens and progestogens and the incidence of gynecologic cancer. Maturitas 1996;23:235–39.

    Article  PubMed  CAS  Google Scholar 

Download references

Authors
  1. P. Sismondi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. N. Biglia
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. M. Giai
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Ponzone
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. C. Campagnoli
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Institute of Pharmacological Sciences, University of Milan, Milan, Italy

    R. Paoletti

  2. Department of Obstetrics and Gynecology, University of Milan, Milan, Italy

    P. G. Crosignani

  3. Department of Obstetrics and Gynaecology, University Hospital Vrije Universiteit, Amsterdam, The Netherlands

    P. Kenemans

  4. Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden

    G. Samsioe

  5. Institute of Pharmacological Sciences, University of Milan, Milan, Italy

    M. R. Soma

  6. Giovanni Lorenzini Medical Foundation, Houston, Texas, USA

    A. S. Jackson (Managing Editor) (Managing Editor)

Rights and permissions

Reprints and permissions

Copyright information

© 1997 Springer Science+Business Media Dordrecht

About this chapter

Cite this chapter

Sismondi, P., Biglia, N., Giai, M., Ponzone, R., Campagnoli, C. (1997). Hormone Replacement Therapy and Breast and Gynecologic Cancers. In: Paoletti, R., Crosignani, P.G., Kenemans, P., Samsioe, G., Soma, M.R., Jackson, A.S. (eds) Women’s Health and Menopause. Medical Science Symposia Series, vol 11. Springer, Dordrecht. https://doi.org/10.1007/978-94-011-5560-1_44

Download citation

  • DOI: https://doi.org/10.1007/978-94-011-5560-1_44

  • Publisher Name: Springer, Dordrecht

  • Print ISBN: 978-94-010-6343-2

  • Online ISBN: 978-94-011-5560-1

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation